Instituto de Química Médica (IQM-CSIC), Juan de la Cierva 3, 28006, Madrid, Spain.
KU Leuven-University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000, Leuven, Belgium.
Antiviral Res. 2019 Aug;168:210-214. doi: 10.1016/j.antiviral.2019.06.006. Epub 2019 Jun 20.
We have previously reported a new class of dendrimers with tryptophan (Trp) residues on the surface that show dual antiviral activities against HIV and enterovirus EV71. The prototype compound of this family is a derivative of pentaerythritol with 12 peripheral Trp groups and trivalent spacer arms. Here a novel series of dendrimers with divalent and tetravalent branched arms, instead of the trivalent ones present on the prototype, has been synthesized and its activity against HIV, EV71 and a panel of 16 different viruses and other pathogens has been determined. Convergent or divergent approaches have been used for the synthesis of these compounds. Our findings demonstrate that only compounds with tetravalent branched arms showed the same anti-HIV and anti-EV71 activity of the prototype (low micromolar) and even gain significant antiviral activity against new pathogens such as HSV-2, adenovirus-2, human corona virus and respiratory syncytial virus, being the first members of the Trp dendrimer family that showed activity against those viruses. As the prototype, these compounds also showed low-nanomolar activity against a representative EV71 clinical isolate. Experimental work carried on to determine the mode of action of the most potent IIa, containing tetravalent branched arms, demonstrated that it interacts with the viral envelopes of HIV, EV71 and HSV-2 and thus may prevent virus attachment to the host cell. These results support the interest of this new series of Trp dendrimers and qualify them as useful prototypes for the development of novel inhibitors of viral entry with broad antiviral spectrum.
我们之前曾报道过一类新型树突状聚合物,其表面带有色氨酸(Trp)残基,对 HIV 和肠道病毒 EV71 具有双重抗病毒活性。该家族的原型化合物是具有 12 个外围色氨酸基团和三价间隔臂的季戊四醇衍生物。在此,我们合成了一系列具有二价和四价支化臂的新型树突状聚合物,取代了原型中的三价支化臂,并测定了其对 HIV、EV71 以及 16 种不同病毒和其他病原体的活性。我们使用了收敛或发散方法来合成这些化合物。我们的研究结果表明,只有具有四价支化臂的化合物才表现出与原型相同的抗 HIV 和抗 EV71 活性(低微摩尔),甚至对新的病原体如单纯疱疹病毒 2(HSV-2)、腺病毒 2(adenovirus-2)、人类冠状病毒和呼吸道合胞病毒具有显著的抗病毒活性,成为首个对这些病毒具有活性的色氨酸树突状聚合物家族成员。与原型一样,这些化合物对代表 EV71 的临床分离株也具有低纳摩尔级的活性。为确定最有效化合物 IIa(含有四价支化臂)的作用模式而进行的实验工作表明,它与 HIV、EV71 和 HSV-2 的病毒包膜相互作用,从而可能阻止病毒与宿主细胞的附着。这些结果支持了这一系列新型色氨酸树突状聚合物的研究兴趣,并证明它们是开发具有广谱抗病毒活性的新型病毒进入抑制剂的有用原型。